bpc-157 danger BPC-157: Experimental Peptide Creates Risk for Athletes BPC-157 benefits, dosage, and side

doi: 10.3389/fphar.2025.1585965 Received 08 March 2025 Accepted 29 July 2025 Published 14 August 2025 Volume 16 - 2025 Edited by Filomena Corbo, University of Bari Aldo Moro, Italy Reviewed by Inas Youssef Younis, Cairo University, Egypt Suryaa Manoharan, Bharathiar University, India Aty Widya Waruyanti, Airlangga University, Indonesia Updates Copyright 2025 Arozal, Eziefule, Wanandi, Louisa, Dewi, Nafrialdi, Siregar and Makambwa

The peptide appears to shift macrophage polarization from pro-inflammatory M1 phenotypes toward anti-inflammatory M2 phenotypes, thereby facilitating tissue repair and regeneration

Solution : Start with 250mcg minimum

Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion

Thyroid considerations Cagrilintide carries a theoretical concern regarding thyroid tumors, similar to the boxed warnings on GLP-1 receptor agonists